Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP

Annals of Hematology

Volumn 86, Issue 2, 2007, Pages 95-100

  Lin, Peng Chan ^a,b,c   Hsiao, Liang Tsai ^a,b   Poh, Say Bee ^a,b   Wang, Wei Shu ^a,b   Yen, Chueh Chuan ^a,b   Chao, Ta Chung ^a,b   Liu, Jin Hwang ^a,b   Chiou, Tzeon Jye ^a,b   Chen, Po Min ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bacterial infection; Diffuse large B cell lymphoma; Fungal infection; Rituximab

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BACTERIAL INFECTION; BONE MARROW METASTASIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYCOSIS; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; INFECTION RATE; LARGE CELL LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; PNEUMONIA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; UNIVARIATE ANALYSIS; VIRUS INFECTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; MYCOSES; PREDNISONE; RISK FACTORS; VINCRISTINE;

EID: 33845719408     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0191-4     Document Type: Article

References (24)

1. Bai LY, Yang MH, Chiou TJ, Liu JH, Yen CC, Wang WS (2003) Non-Hodgkin lymphoma in elderly patients: Experience at Taipei Veterans General Hospital. Cancer 98:1188-1195
2. Gomez H, Hidalgo M, Casanova L, Colomer R, Pen DL, Otero J (1998) Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. J Clin Oncol 16:2065-2069
3. Peters FP, Lalisang RI, Fickers MM, Erdkamp FL, Wils JA, Houben SG (2001) Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: A retrospective population-based study. Ann Hematol 80:155-159
4. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
5. Italiano A, Jardin F, Peyrade F, Saudes L, Tilly H, Thyss A (2005) Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica 90:1281-1283
6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
7. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan (2005) J Microbiol Immunol Infect 38:455-457
8. Bone RC (1992) Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268:3452-3455
9. Cheng MF, Yang YL, Yao TJ, Lin CY, Liu JS, Tang RB (2005) Risk factors for fatal candidemia caused by Candida albicans and non- albicans Candida species. BMC Infect Dis 5:22
10. Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A (1988) Risk factors for candidemia in cancer patients: A case-control study. J Clin Microbiol 26:429-432
11. Ribeiro P, Sousa AB, Nunes O, Aveiro F, Fernandes JP, Gouveia J (1997) Candidemia in acute leukemia patients. Support Care Cancer 5:249-251
12. Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T (2004) Invasive fungal infections in autologous stem cell transplant recipients: A nation-wide study of 1188 transplanted patients. Eur J Haematol 73:174-178
13. Safdar A, Singhal S, Mehta J (2004) Clinical significance of non- Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001) Cancer 100:2456-2461
14. Crameri R, Blaser K (2002) Allergy and immunity to fungal infections and colonization. Eur Respir J 19:151-157
15. Scheinfeld N (2005) Infections in the elderly. Dermatol Online J 11:8
16. Fridkin SK, Jarvis WR (1996) Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 9:499-511
17. Guven GS, Uzun O, Cakir B, Akova M, Unal S (2005) Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: A retrospective cohort study (1997-2001). Support Care Cancer 14(1):52-55
18. Cornely OA, Ullmann AJ, Karthaus M (2004) [Opportunistic infections after treatment with monoclonal antibodies]. Wien Med Wochenschr 154:209-217
19. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195
20. Buchanan KL, Murphy JW (1993) Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun 61:2854-2865
21. Murphy JW (1993) Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response. Infect Immun 61:4750-4759
22. Murphy JW, Hidore MR, Wong SC (1993) Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans. J Clin Invest 91:1553-1566
23. Cassone A, Conti S, De Bernardis F, Polonelli L (1997) Antibodies, killer toxins and antifungal immunoprotection: A lesson from nature? Immunol Today 18:164-169
24. Bishop JF, Schimpff SC, Diggs CH, Wiernik PH (1981) Infections during intensive chemotherapy for non-Hodgkin's lymphoma. Ann Intern Med 95:549-555